Invivyd (IVVD) Proxy filing summary

Executive summary

• The annual meeting is scheduled for May 19, 2026, to be held virtually, with voting on director elections and auditor ratification as the main agenda items.

• Stockholders of record as of March 20, 2026, are eligible to vote, with 282,803,863 shares outstanding.

• Proxy materials, including the annual report, are available online, and multiple voting methods are provided.

Voting matters and shareholder proposals

• Proposal 1: Election of six directors for a one-year term expiring at the 2027 annual meeting.

• Proposal 2: Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.

• Board recommends voting FOR all director nominees and FOR auditor ratification.

• Procedures for submitting shareholder proposals for the 2027 meeting are detailed, with specific deadlines and requirements.

Board of directors and corporate governance

• Six director nominees, all determined to be independent, with diverse backgrounds in biotech, finance, and technology.

• Board leadership is separated between an independent chairperson and the principal executive officer.

• Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, each with independent members.

• Board and committee meetings had high attendance, and directors are encouraged to attend annual meetings.

• Policies in place for insider trading prevention, hedging, and clawback of incentive compensation.